Intersectional insights from an MDMA-assisted psychotherapy training trial: An open letter to racial/ethnic and sexual/gender minorities
Journal of Psychedelic Studies July 24, 2019 DOI: 10.1556/2054.2019.017 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open letter Peer reviewed |
|---|---|
| Topics | MDMA Psychedelic-assisted therapy |
| Key points | The author argues that political and academic bias, as well as cultural stigma, are barriers to minority inclusion in MDMA research, and calls for greater attention to intersecting identities and minority participation. |
Abstract
The road to the current psychedelic renaissance in research on ±3,4-methylenedioxymethamphetamine (MDMA) – the active ingredient of the drug Ecstasy – for addressing treatment-resistant post-traumatic stress disorder has been fraught with political and academic bias, as well as cultural stigma among underserved populations, all of which serve as barriers to minority inclusion and participation. In this open letter to ethnic/racial and sexual/gender minorities, the author details intersectional insights from his own experience being administered MDMA legally as part of a therapist training trial for MDMA-assisted psychotherapy, in hopes of radically destigmatizing this treatment approach for marginalized populations. Themes covered include: set and setting; cultural pride; LGBTQIA+ pride; acceptance of intersectionality; and patience, perspective, and strength in retrospection. This letter concludes by tasking current investigators of MDMA-assisted psychotherapy to emphasize issues of intersecting identities (e.g., in terms of race, ethnicity, sexual orientation, and gender identity) in their research agenda, attempt to improve minority participation in a culturally attuned manner, as well as increase minority stakeholdership in this field.
Citations in the library
Cited by 18
- Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder Journal of Psychedelic Studies July 30, 2019
- Diversity, equity, and access in psychedelic medicine Journal of Psychedelic Studies December 27, 2019
- The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision Frontiers in Psychiatry January 20, 2022
- Counselors’ attitudes toward psychedelics and their use in therapy Journal of Counseling & Development March 19, 2022
- MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials Frontiers in Psychiatry October 10, 2022
and 13 more in the library
Cites 17
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology Journal of Psychopharmacology November 16, 2016
- Constructing drug effects: A history of set and setting Drug Science, Policy and Law 2017
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
- Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. Journal of Psychopharmacology 2013
and 12 more in the library